{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:06:38Z","timestamp":1790139998540,"version":"4.0.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the impact of administering nafamostat through central venous catheter versus extracorporeal membrane oxygenation (ECMO) circuit on anticoagulation efficacy during ECMO support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective study included patients who received nafamostat for anticoagulation during ECMO support. Collected clinical data included age, sex, body weight, indication for ECMO, medical history, vital signs, laboratory test results, complications, and clinical outcomes. Patients were categorized into a central venous administration group and an ECMO-circuit administration group according to the site of nafamostat administration. Clinical parameters and outcomes were compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 102 patients were included in the analysis. The mean age was 51\u2009\u00b1\u20099 years, with 61 (59.8%) males and 41 (40.2%) females. There were no statistically significant differences between the two groups in age, body weight, sex distribution, ECMO indications, medical history, vital signs, laboratory findings, or acute physiology and chronic health evaluation II (APACHE II) scores (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05). The incidence of membrane oxygenator thrombosis was significantly higher in the central venous group than in the ECMO-circuit group (32.6% vs. 12.5%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Central venous infusion of nafamostat was associated with an increased risk of membrane oxygenator thrombosis (OR:3.491, 95%CI 1.270\u20139.593,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). The time required to achieve the anticoagulation target was significantly longer in the central venous group [4 (3\u20135) vs. 3 (3\u20134) hours,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05], and the mean daily dose of nafamostat was also significantly higher (1210\u2009\u00b1\u2009261 vs. 1084\u2009\u00b1\u2009132\u2005mg,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with central venous infusion, administration of nafamostat via the ECMO circuit was associated with a lower incidence of membrane oxygenator thrombosis, more rapid achievement of the anticoagulation target, and a lower daily dosage requirement. These findings are hypothesis-generating and require confirmation in prospective studies before informing clinical decisions regarding the route of nafamostat administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1876688","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:46:41Z","timestamp":1790138801000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anticoagulant effects of nafamostat administered via central venous catheter versus the ECMO circuit in adults receiving ECMO support"],"prefix":"10.3389","volume":"13","author":[{"given":"Xinmei","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, Affiliated Jinhua Hospital Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Affiliated Jinhua Hospital Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Affiliated Jinhua Hospital Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Unit, The First Hospital of Jiaxing","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Affiliated Jinhua Hospital Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Affiliated Jinhua Hospital Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Pan\u2019an County People's Hospital","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s13054-022-04249-w","article-title":"Parameters associated with successful weaning of veno-arterial extracorporeal membrane oxygenation: a systematic review","volume":"26","author":"Charbonneau","year":"2022","journal-title":"Crit Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/MAT.0000000000001230","article-title":"Thrombosis and bleeding in extracorporeal membrane oxygenation (ECMO) without anticoagulation: a systematic review","volume":"67","author":"Olson","year":"2021","journal-title":"ASAIO J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/MAT.0000000000001605","article-title":"Thrombosis in extracorporeal membrane oxygenation (ECMO) circuits","volume":"68","author":"Figueroa Villalba","year":"2022","journal-title":"ASAIO J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.21037\/acs.2018.12.02","article-title":"Heparin-induced thrombocytopenia during extracorporeal life support: incidence, management and outcomes","volume":"8","author":"Choi","year":"2019","journal-title":"Ann Cardiothorac Surg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1111\/aor.14276","article-title":"Use of nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: a systematic review","volume":"46","author":"Sanfilippo","year":"2022","journal-title":"Artif Organs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijcard.2022.07.022","article-title":"Anticoagulation with nafamostat mesilate during extracorporeal life support","volume":"366","author":"Lang","year":"2022","journal-title":"Int J Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1541131","DOI":"10.3389\/fphar.2025.1541131","article-title":"Pharmacokinetic and pharmacodynamic analyses of nafamostat in ECMO patients: comparing central vein and ECMO machine samples","volume":"16","author":"Lee","year":"2025","journal-title":"Front Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.athoracsur.2016.01.044","article-title":"Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate versus heparin","volume":"102","author":"Lim","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/aor.70162","article-title":"Anticoagulation strategies in adults undergoing extracorporeal membrane oxygenation: a systematic review and meta-analysis","volume":"50","author":"Scharner","year":"2026","journal-title":"Artif Organs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12959-022-00401-2","article-title":"Evaluation of clinical outcomes in patients treated with heparin or direct thrombin inhibitors during extracorporeal membrane oxygenation: a systematic review and meta-analysis","volume":"20","author":"M'Pembele","year":"2022","journal-title":"Thromb J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/MAT.0000000000001598","article-title":"Comparison of bivalirudin versus unfractionated heparin for anticoagulation in adult patients on extracorporeal membrane oxygenation","volume":"68","author":"Sheridan","year":"2022","journal-title":"ASAIO J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/phar.2859","article-title":"Anticoagulation strategies in patients with extracorporeal membrane oxygenation: a network meta-analysis and systematic review","volume":"43","author":"Chen","year":"2023","journal-title":"Pharmacotherapy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3390\/molecules27061881","article-title":"Pharmacokinetics of nafamostat, a potent serine protease inhibitor, by a novel LC-MS\/MS analysis","volume":"27","author":"Oh","year":"2022","journal-title":"Molecules"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s40262-022-01170-x","article-title":"Nafamostat mesylate for treatment of COVID-19 in hospitalised patients: a structured, narrative review","volume":"61","author":"Hern\u00e1ndez-Mitre","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.61882\/ijkd.19.1.41","article-title":"Effects of nafamostat mesilate and systemic unfractionated heparin anticoagulation on coagulation, renal function, and 28-day survival status in critically ill AKI CRRT patients","volume":"19","author":"Zhan","year":"2025","journal-title":"Iran J Kidney Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40001-024-01660-7","article-title":"Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study","volume":"29","author":"Liu","year":"2024","journal-title":"Eur J Med Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/sdi.12946","article-title":"Continuous renal replacement therapy without anticoagulation in critically ill patients at high risk of bleeding: a systematic review and meta-analysis","volume":"34","author":"Zhang","year":"2021","journal-title":"Semin Dial"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1876688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:46:48Z","timestamp":1790138808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1876688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":17,"alternative-id":["10.3389\/fcvm.2026.1876688"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1876688","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1876688"}}